A molecular understanding of the events responsible for Streptococcus pneumoniae (Spn) organ invasion
during bacteremia remains elusive although its consequences are devastating. We have closely examined the
interaction between capsule and vascular endothelial cells (VEC) and developed the hypothesis that capsule
dynamics are complex and impact all stages of Spn translocation across VEC. This includes attachment,
receptor mediated endocytosis (RME), resistance to intracellular killing, and trafficking to the basolateral
surface for organ invasion. Testing of our hypothesis will reveal the intracellular mechanics of Spn trafficking
that drive organ invasion. Our results will impact risk assessment strategies for serotype-based vaccine design.
AIM 1. Determine how serotype impacts platelet-activating factor receptor (PAFr) and laminin-receptor
initiated adhesion/uptake of Spn. Our preliminary results indicate capsule has serotype-variable antagonistic
effects on the bacterium's interaction with host cells that affects RME. We will use a comprehensive panel of
isogenic capsule switch mutants of low and high invasive disease capability, specifically focusing on serotypes
belonging to the same serogroup, i.e., having single and defined molecular differences in their capsule
structure, to determine how specific biochemical features, such as acetylation, affect interactions with both
peripheral and cerebral VEC. We will quantify serotype dependence of surface exposure of the Spn adhesins
phosphorylcholine (PC) and choline binding protein A (CbpA), its effect on adhesion to their ligands PAFr and
LR, respectively, on receptor-initiated signaling responsible for uptake, and in summate, on invasion rate.
AIM 2. Determine how serotype influences the path taken by intracellular Spn for translocation vs
recycling vs removal. The degradation of cargo taken up by RME in non-phagocytic cells is mediated by the
novel LC3-associated endocytic recycling pathway `LANDO'. Thus, LANDO is likely a critical pathway co-opted
by the pneumococcus to cross VEC. Using low and highly invasive capsule mutant swaps, we will determine
the ability of PAFr and LR to initiate LANDO. We will subsequently determine the impact of capsule and
serotype on Spn trafficking across wild type vs LANDO deficient VEC in vitro. We will characterize targeting of
Spn into heart and brain of pafr-/-, LANDO deficient, and LR-blocked mice, thereby assessing how capsule
modulates vital endocytic processes at the crossroads of bacterial translocation vs death in the lysosome.
AIM 3. Determine how capsule shedding impacts bacterial fate within VEC. Whereas pneumococci in the
bloodstream are encapsulated when taken up by VEC, our results suggest capsule is shed within the
endosome following RME and provides protection from low pH and oxidative stress which are deployed to kill
the bacterium. We will determine the status of capsule (shed or unshed) and the importance of shedding on
Spn as they cross the VEC. We will determine if serotype impacts the kinetics of capsule shedding by Spn and
how capsule type and shedding influences endosome acidification and lysosome fusion.